The temporal profile of inflammatory markers and mediators in blood after acute ischemic stroke differs depending on stroke outcome

Cerebrovascular Diseases

Volumn 30, Issue 1, 2010, Pages 85-92

  Worthmann, H ^a   Tryc, A B ^a   Goldbecker, A ^a   Ma, Y T ^a,c   Tountopoulou, A ^a   Hahn, A ^b   Dengler, R ^a   Lichtinghagen, R ^b   Weissenborn, K ^a  

^a Department of Neurology ^*  (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

CRP; Cytokines; IL 6; Inflammation; Ischemic stroke; MCP 1; MMP 9; S100B; TIMP 1

Indexed keywords

C REACTIVE PROTEIN; GELATINASE B; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; PROTEIN S100B; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; BRAIN ISCHEMIA; CONTROLLED STUDY; DISEASE MARKER; FEMALE; HOSPITAL ADMISSION; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SCORING SYSTEM; TRANSIENT ISCHEMIC ATTACK;

AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS; BIOLOGICAL MARKERS; BRAIN ISCHEMIA; C-REACTIVE PROTEIN; CHEMOKINE CCL2; CHI-SQUARE DISTRIBUTION; DISABILITY EVALUATION; FEMALE; GERMANY; HUMANS; INFLAMMATION MEDIATORS; INTERLEUKIN-6; ISCHEMIC ATTACK, TRANSIENT; LINEAR MODELS; LOGISTIC MODELS; MALE; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; NERVE GROWTH FACTORS; PROGNOSIS; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; S100 PROTEINS; STROKE; TIME FACTORS; TISSUE INHIBITOR OF METALLOPROTEINASE-1;

EID: 77952309802     PISSN: 10159770     EISSN: None     Source Type: Journal    
DOI: 10.1159/000314624     Document Type: Article

References (31)

1. Mergenthaler P, Dirnagl U, Meisel A: Pathophysiology of stroke: lessons from animal models. Metab Brain Dis 2004; 19: 151-167.
2. Garcia JH, Liu KF, Yoshida Y, Lian J, Chen S, del Zoppo GJ: Influx of leukocytes and platelets in an evolving brain infarct (Wistar rat). Am J Pathol 1994; 144: 188-199.
3. Justicia C, Panes J, Sole S, Cervera A, Deulofeu R, Chamorro A, Planas AM: Neutrophil infiltration increases matrix metalloproteinase-in the ischemic brain after occlusion/ reperfusion of the middle cerebral artery in rats. J Cereb Blood Flow Metab 2003; 23: 1430-1440.
4. Fujimura M, Gasche Y, Morita-Fujimura Y, Massengale J, Kawase M, Chan PH: Early appearance of activated matrix metalloproteinase- and blood-brain barrier disruption in mice after focal cerebral ischemia and reperfusion. Brain Res 1999; 842: 92-100. (Pubitemid 29447856)
5. Gelderblom M, Leypoldt F, Steinbach K, Behrens D, Choe CU, Siler DA, Arumugam TV, Orthey E, Gerloff C, Tolosa E, Magnus T: Temporal and spatial dynamics of cerebral immune cell accumulation in stroke. Stroke 2009; 40: 1849-1857.
6. Winbeck K, Poppert H, Etgen T, Conrad B, Sander D: Prognostic relevance of early serial C-reactive protein measurements after first ischemic stroke. Stroke 2002; 33: 2459-2464.
7. Rallidis LS, Vikelis M, Panagiotakos SB, Rizos I, Zolindaki MG, Kaliva K, Kremastinos DT: Inflammatory markers and in-hospital mortality in acute ischaemic stroke. Atherosclerosis 2006; 189: 193-197.
8. Montaner J, Alvarez-Sabin J, Molina C, Anglés A, Abilleira S, Arenillas J, González MA, Monasterio J: Matrix metalloproteinase expression after human cardioembolic stroke: temporal profile and relation to neurological impairment. Stroke 2001; 32: 1759-1766.
9. Horstmann S, Kalb P, Koziol J, Gardner H, Wagner S: Profiles of matrix metalloproteinases, their inhibitors, and laminin in stroke patients: influence of different therapies. Stroke 2003; 34: 2165-2170.
10. Castillo J, Rodriguez I: Biochemical changes and inflammatory response as markers for brain ischaemia: molecular markers of diagnostic utility and prognosis in human clinical practice. Cerebrovasc Dis 2004; 17(suppl 1):7-18.
11. Gourmala NG, Buttini M, Limonta S, Sauter A, Boddeke HW: Differential and time-dependent expression of monocyte chemoattractant protein-1 mRNA by astrocytes and macrophages in rat brain: effects of ischemia and peripheral lipopolysaccharide administration. Neuroimmunology 1997; 74: 35-44.
12. Castellanos M, Leira R, Serena J, Pumar JM, Lizasoain I, Castillo J, Dávalos A: Plasma metalloproteinase-9 concentration predicts hemorrhagic transformation in acute ischemic stroke. Stroke 2003; 34: 40-46.
13. Lorenzl S, De Pasquale G, Segal AZ, Beal MF: Dysregulation of the levels of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases in the early phase of cerebral ischemia. Stroke 2003; 34:e37-e38.
14. Whiteley J, Jackson C, Lewis S, Lowe G, Rumley A, Sandercock P, Wardlaw J, Dennis M, Sudlow C: Inflammatory markers and poor outcome after stroke: a prospective cohort study and systematic review of interleukin- 6. PLoS Med 2009; 6:e1000147.
15. Missler U, Wiesmann M, Friedrich C, Kaps M: S-100 protein and neuron-specific enolase concentrations in blood as indicators of infarction volume and prognosis in acute ischemic stroke. Stroke 1997; 28: 1956-1960.
16. Foerch C, Otto B, Singer OC, Neumann- Haefelin T, Yan B, Berkefeld J, Steinmetz H, Sitzer M: Serum S100B predicts a malignant course of infarction in patients with acute middle cerebral artery occlusion. Stroke 2004; 35: 2160-2164.
17. Wunderlich MT, Ebert AD, Kratz T, Goertler M, Jost S, Herrmann M: Early neurobehavioral outcome after stroke is related to release of neurobiochemical markers of brain damage. Stroke 1999; 30: 1190-1195.
18. McColl BW, Allan SM, Rothwell NJ: Systemic infection, inflammation and acute ischemic stroke. Neuroscience 2009; 158: 1049-1061.
19. National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group: Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995; 333: 1581-1587.
20. Sotgiu S, Zanda B, Marchetti B, Fois ML, Arru G, Pes GM, Salaris FS, Arru A, Pirisi A, Rosati G: Inflammatory biomarkers in blood of patients with acute brain ischemia. Eur J Neurol 2006; 13: 505-513.
21. Vila N, Castillo J, Davalos A, Chamorro A: Proinflammatory cytokines and early neurological worsening in ischemic stroke. Stroke 2000; 31: 2325-2329.
22. Smith CJ, Emsley HC, Gagin CM, Georgiou RF, Vail A, Barberan EM, del Zoppo GJ, Hallenbeck JM, Rothwell NJ, Hopkins SJ, Tyrrell PJ: Peak plasma interleukin-6 and other peripheral markers of inflammation in the first week of ischaemic stroke correlate with brain infarct volume, stroke severity and longterm outcome. BMC Neurol 2004; 15: 2.
23. Waje-Andreassen U, Krakenes J, Ulvestad E, Thomassen L, Myhr KM, Aarseth J, Vedeler CA: IL-6: an early marker for outcome in acute ischemic stroke. Acta Neurol Scand 2005; 111: 360-365.
24. Elkind MS, Coates K, Tai W, Paik MC, Boden-Albala B, Sacco RL: Levels of acute phase proteins remain stable after ischemic stroke. BMC Neurol 2006; 6: 37.
25. Welsh P, Barber M, Langhorne P, Rumley A, Lowe GD, Stott DJ: Associations of inflammatory biomarkers with poor outcome in acute ischaemic stroke. Cerebrovasc Dis 2009; 27: 247-253.
26. Song IU, Kim JS, Kim YI, Lee KS, Jeong DS, Chung SW: Relationship between high-sensitivity C-reactive protein and clinical functional outcome after acute ischemic stroke in a Korean population. Cerebrovasc Dis 2009; 28: 545-550.
27. Hughes PM, Allegrini PR, Rudin M, Perry VH, Mir AK, Wiessner C: Monocyte chemoattractant protein-1 deficiency is protective in a murine stroke model. J Cereb Blood Flow Metab 2002; 22: 308-317.
28. Heo JH, Lucero J, Abumiya T, Koziol JA, Copeland BR, del Zoppo GJ: Matrix metalloproteinases increase very early during experimental focal cerebral ischemia. J Cereb Blood Flow Metab 1999; 19: 624-633.
29. Kouwenhoven M, Carlström C, Özenci V, Link H: Matrix metalloproteinase and cytokine profiles in monocytes over the course of stroke. J Clin Immunol 2001; 21: 365-374.
30. Brew K, Dinakarpandian D, Nagase H: Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochim Biophys Acta 2000; 1477: 267-283.
31. Dassan P, Keir G, Brown M: Criteria for a clinically informative serum biomarker in acute ischaemic stroke: a review of S100B. Cerebrovasc Dis 2009; 27: 295-302.